95. Nomura Y, Ota Y, Fujita Y, et al.

94. Bissen-Miyajima H, Ota Y, Taira Y, et al.

93. Matsuura N, Kanayama M, Watanabe Y, et al.

92. Nakajima H, Okada H, Kogure A, et al.

91. Kawabata S, Nagai S, Ito K, et al.

90. Sumida Y, Toyoda H, Yasuda S, et al.

89. Fukuda M, Sakuma I, Wakasa Y, et al.

88. Tomita T, Fukui H, Okugawa T, et al.

87. Mita T, Katakami N, Yoshii H, et al.

86. Mita T, Katakami N, Okada Y, et al.

85. Takuma K, Fuchigami A, Shigiyama F, et al.

84. Ishii H, Kamei N, Shimono D, et al.

83. Tamura Y, Kaga H, Abe Y, et al.

82. Sugawara M, Fukuda M, Sakuma I, et al.

81. Katakami N, Mita T, Yoshii H, et al.

80. Hiruma S, Shigiyama F, Kumashiro N.

79. Osonoi T, Saito M, Hosoya M, et al.

78. Nakajima H, Okada H, Kogure A, et al.

77. Hamaguchi M, Yoshimura Y, Nakajima H, et al.

76. Komorizono Y, Hosoyamada K, Imamura N, et al.

75. Hiruma S, Shigiyama F, Hisatake S, et al.

74. Kawakami T, Kohsaka S, Sato Y, et al.

Standards for assessing and reporting adverse events.
Lancet Respiratory Medicine. 2022; 10: E110-E111

73. Yamamoto K, Hosogaya N, Inoue T, et al.

Efficacy of Lactococcus lactis strain plasma (LC-Plasma) in easing symptoms in patients with mild coronavirus disease (COVID-19): protocol for an exploratory, multicenter, double-blinded, randomized controlled trial (PLATEAU study).
BMJ Open.2022 Sep; 12:e061172.

72. Yoshii H, Mita T, Katakami N, et al.

The importance of continuous glucose monitoring-derived metrics beyond HbA1c for optimal individualized glycemic control.
J Clin Endocrinol Metab.2022 Jul; 107: e3990–e4003.

71. Katakami N, Mita T, Maeda N, et al.

Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall-a sub-analysis of the UTOPIA trial.
Cardiovasc Diabetol.2022 Feb; 21:19.

70. Kawakami T, Matsubara H, Shinke T, et al.

Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial.
Lancet Respiratory Medicine.2020 Sep; 10: 949-960.

69. Kurozumi A, Okada Y, Mita T, et al.

Associations between continuous glucose monitoring-derived metrics and HbA1c in patients with type 2 diabetes mellitus..
Diabetes Res Clin Pract.2022 Apr; 186:109836.

68. Uemura F, Okada Y, Mita T, et al.

Risk factor analysis for type 2 diabetic patients about hypoglycemia using continuous glucose monitoring: Results from a prospective observational study.
Diabetes Technology and Therapeutics.2022 May; 24:435-445.

67. Sakuma M, Toyoda S, Arikawa T, et al.

Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial.
PLoS One.2022 Jan; 17:e0261445.

66. Hamaguchi M, Hashimoto Y, Tanaka T, et al.

Multicenter, Open-Label, 2-Arm, Pilot Trial for Safe Reduction of Basal Insulin Dose Combined with SGLT2 Inhibitor in Type 1 Diabetes Mellitus: Study Protocol for a RISING-STAR Trial.
Clin Med Insights Endocrinol Diabetes.2021 Sep; 14:1-16.

65. Hata S, Hakajima H, Hashimoto Y, et al.

Effects of probiotic Bifidobacterium bifidum G9-1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus: an open-label, single-arm, exploratory research trial.
J Diabetes Investig.2022 Mar; 13: 489-500.

64. Hashimoto Y, Nakajima H, Hata S, et al.

Effect of probiotics, Bifidobacterium bifidum G9-1, on gastrointestinal symptoms in patients with type 2 diabetes mellitus: study protocol for open-label, single-arm, exploratory research trial (Big STAR study).
J Clin Biochem Nutr.2020 Sep; 67:223-227.

63. Tokutsu A, Okada Y, Mita T, et al.

Relationship between blood glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics: Subanalysis of a prospective cohort study.
Diabetes Obes Metab.2021 Dec; 24:82-93.

62. Yamamoto K, Hosogaya N, Sakamoto N, et al.

Efficacy of clarithromycin in patients with mild COVID-19 pneumonia not receiving oxygen administration: protocol for an exploratory, multicenter, open-label, randomized-controlled trial (CAME COVID study).
BMJ Open.2021 Sep; 11:e053325.

61. Katakami N, Mita T, Yoshii H, et al.

The influence of tofogliflozin on treatment-related quality of life in patients with type 2 diabetes mellitus.
Diabetes Ther. 2021 Aug; 12:2499-2515.3.

60. Sakata R, Fujishiro T, Saito H, et al.

The Additive Effect of ROCK Inhibitor on Prostaglandin-Treated Japanese Patients with Glaucoma Indicating 15 mmHg and Under: ROCK U-15.
Adv Ther. 2021 Jul; 38:3760-3770.

59. Taya N, Katakami N, Mita T, et al.

Associations of Continuous Glucose Monitoring-assessed Glucose Variability with Intima-Media Thickness and Ultrasonic Tissue Characteristics of the Carotid Arteries: A Cross-Sectional Analysis in Patients with Type 2 Diabetes.
Cardiovasc Diabetol. 2021 May; 20:95.

58. Takahara M, Shiraiwa T, Maeno Y, et al.

Association of obesity, diabetes, and physical frailty with dental and tongue-lip motor dysfunctions in patients with metabolic disease.
Obes Res Clin Pract. 2021 May; 15:243-248.

57. Kanazawa A, Aida M, Yoshida Y et al.

Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study.
Nutrients. 2021 Feb 8;13(2):558.

56. Hiroaki Seino

Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Complicated by Hepatic Dysfunction: A Single-Site, Single-Arm, Open-Label, Exploratory Trial.
Diabetes Ther. 2021 Mar;12(3):863-877.

55. Katsuno T, Shiraiwa T, Iwasaki S et al.

Benefit of Early Add-on of Linagliptin to Insulin in Japanese Patients With Type 2 Diabetes Mellitus: Randomized-Controlled Open-Label Trial (TRUST2).
Adv Ther. 2021 Mar;38(3):1514-1535.

54. Katakami N, Mita T, Yoshii H et al.

Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
Cardiovasc Diabetol. 2021 Jan 4;20(1):4.

53. Ishii H, Nakajima H, Kamei N et al.

Comparison of Patient-Led and Physician-Led Insulin Titration in Japanese Type 2 Diabetes Mellitus Patients Based on Treatment Distress, Satisfaction, and Self-Efficacy: The COMMIT-Patient Study.
Diabetes Ther. 2021 Feb;12(2):595-611.

52. Wakasugi S, Mita T, Katakami N et al.

Associations between continuous glucose monitoring-derived metrics and arterial stiffness in Japanese patients with type 2 diabetes.
Cardiovasc Diabetol. 2021 Jan 7;20(1):15.

51. Ishii H, Nakajima H , Kamei N, et al.

Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study) .
Diabetes Ther. 2020 Dec;11(12):2959-2977.

50. Ishibashi R, Takatsuna Y, Koshizaka M, et al.

Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled Trial.
Diabetes Ther. 2020 Aug;11(8):1891-1905.

49. Kayano H, Koba S, Hirano T, et al.

Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients　― A Randomized Controlled Trial ―.
Circ J. 2020 Volume 84 Issue 10, 1807-1817

48. Katakami N, Mita T, Yoshii H, et al.

Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.
Cardiovasc Diabetol. 2020 Jul 9;19(1):110.

47. Ohtake T, Mochida Y, Ishioka K, et al.

Improvement of microcirculatory impairment in patients with predialysis chronic kidney disease after AST-120 administration.
Ren Replace Ther. 6, 28 (2020).

46. Kitazawa T, Seino H, Ohashi H, et al.

Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase‐4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24‐week, open‐label, controlled trial (STOP‐OB).
Diabetes Obes Metab. 2020 Sep;22(9):1659-1663.

45. Takahara M, Fukuda M, Matsuzawa Y, et al.

Effect of tasteless calorie-free gum chewing before meal on postprandial plasma glucose, insulin, glucagon, and gastrointestinal hormones in Japanese men without diagnosed glucose metabolism disorder: a pilot randomized crossover trial.
Diabetol Int.(2020). 11: 394–402.

44. Tanaka A, Suzuki M, Matsunaga K, et al.

Effect of rivaroxaban on urinary albumin excretion in patients with atrial fibrillation and chronic kidney disease: a randomized trial (X-NOAC).
Hypertens Res. 2020 Jun;43(6):571-574.

43. Kawakami T, Matsubara H, Abe K, et al.

Multicentre randomised controlled trial of balloon pulmonary angioplasty and riociguat in patients with chronic thromboembolic pulmonary hypertension: protocol for the MR BPA study.
BMJ Open. 2020 Feb 6;10(2):e028831.

42. Fuchigami A, Shigiyama F, Kitazawa T, et al.

Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
Cardiovasc Diabetol. 2020 Jan 7;19(1):1.

41. Igarashi H, Shigiyama F, Wakui N, et al.

Whole hepatic lipid volume quantification and color mapping by multi‐slice and multi‐point magnetic resonance imaging.
Hepatol Res. 2019 Dec;49(12):1374-1385.

40. Mita T, Katakami N, Okada Y, et al.

Protocol of a Prospective Observational Study on the Relationship Between Glucose Fluctuation and Cardiovascular Events in Patients with Type 2 Diabetes.
Diabetes Ther. 2019 Oct;10(5):1565-1575.

39. Shigiyama F, Hiruma S, Hisatake S, et al.

Rationale, Design for the ASSET Study: A Prospective Randomized Study Comparing Empagliflozin’s Effect to Sitagliptin on Cardiac Fat Accumulation/Function in Patients with Type 2 Diabetes.
Diabetes Ther. 2019 Jun 6. 10: 1509–1521.

38. Torimoto K, Okada Y, Goshima Y, et al.

Addition of canagliflozin to insulin improves glycaemic control and reduces insulin dose in patients with type 2 diabetes mellitus: A randomized controlled trial.
Diabetes Obes Metab. 2019 May 10. 21: 2174-2179.

37. Toyoda S, Arikawa T, Inami S, et al.

Patients With CONgestive Heart Failure Benefit From Long-Term Treatment Effects With Novel Treatment Using Azosemide Compared With Furosemide Derived From Existing Retrospective Study Data: CONTENTED.
J Cardiovasc Pharmacol. 2019 Jun;73(6):365-372.

36. Tsuno N, Mori T, Ishikawa I, et al.

Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer’s disease: The Attitude Towards Food Consumption in Alzheimer’s Disease Patients Revive with Rivastigmine Effects study.
Geriatr Gerontol Int. 2019 Mar 12.

35. Mita T, Hiyoshi T, Yoshii H, et al.

The Effect of Linagliptin versus Metformin Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus.
Diabetes Ther. 2019 Feb;10(1):119-134.

34. Katahira T, Kanazawa A, Shinohara M, et al.

Postprandial Plasma Glucagon Kinetics in Type 2 Diabetes Mellitus: Comparison of Immunoassay and Mass Spectrometry.
J Endocr Soc. 2018 Oct 26;3(1):42-51.

33. Yoshikawa F, Kumashiro N, Shigiyama F, et al.

Efficacy of intermittent empagliflozin supplementation on dietary self-management and glycaemic control in patients with poorly controlled type 2 diabetes: A 24-week randomized controlled trial.
Diabetes Obes Metab. 2019 Feb;21(2):303-311.

32. Ishihara H, Anai M, Seino H, et al.

Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy.
Diabetes Ther. 2018 Oct;9(5):2117-2125.

31. Fukuda M, Doi K, Sugawara M, et al.

Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia.
J Diabetes Investig. 2019 Mar;10(2):383-391.

30. Nakaue J, Koizumi M, Nakajima H, et al.

Development of a self-efficacy questionnaire, ‘Insulin Therapy Self-efficacy Scale (ITSS)’, for insulin users in Japanese: The Self-Efficacy-Q study.
J Diabetes Investig. 2019 Mar;10(2):358-366.

29. Sakuma M, Toyoda S, Arikawa T, et al.

The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol.
Clin Exp Nephrol. 2018 Dec;22(6):1379-1386.

28. Shigiyama F, Kumashiro N, Fuchigami A, et al.

Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
Cardiovasc Diabetol. 2018 Jun 12;17(1):86.

27. Mita T, Hiyoshi T, Yoshii H, et al.

Study Protocol for the Initial Choice of DPP-4 Inhibitor in Japanese Patients with Type 2 diabetes Mellitus: Effect of Linagliptin on QOL (INTEL-QOL) Trial.
Diabetes Ther. 2018 Jun;9(3):1403-1412.

26. Goto H, Mita T, Fujitani Y, et al.

Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study.
Endocr J. 2018 Jun 27;65(6):657-668.

25. Nakajima H, Okada S, Mohri T, et al.

Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study).
Diabetol Metab Syndr. 2018 Mar 1;10:11.

24. Katakami N, Mita T, Irie Y, et al.

Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE).
Cardiovasc Diabetol. 2018 Feb 5;17(1):24.

23. Irie Y, Katakami N, Mita T, et al.

Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial.
Diabetes Ther. 2018 Feb;9(1):317-329.

22.Kuroda A, Setoguchi M, Uchino Y, et al.

Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer’s disease.
Geriatr Gerontol Int. 2018 Jun;18(6):886-891.

21. Kurozumi A, Okada Y, Satoh H, et al.

Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: linagliptin study of effects on postprandial blood glucose (L-STEP) sub-study 1.
Endocr J. 2018 Apr 26;65(4):415-425.

20. Katakami N, Mita T, Gosho M, et al.

Clinical Utility of Carotid Ultrasonography in the Prediction of Cardiovascular Events in Patients with Diabetes: A Combined Analysis of Data Obtained in Five Longitudinal Studies.
J Atheroscler Thromb. 2018 Oct 1;25(10):1053-1066.

19. Murata M, Kawakami T, Kataoka M, et al.

Riociguat, a soluble guanylate cyclase stimulator, ameliorates right ventricular contraction in pulmonary arterial hypertension.
Pulm Circ. 2018 Jan-Mar;8(1):2045893217746111.

18. Suzuki L, Kanazawa A, Uzawa H, et al.

Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin.
Expert Opin Pharmacother. 2017 Dec;18(18):1921-1928.

17. Sato J, Kanazawa A, Azuma K, et al.

Probiotic reduces bacterial translocation in type 2 diabetes mellitus: A randomised controlled study.
Sci Rep. 2017 Sep 21;7(1):12115.

16. Katakami N, Mita T, Yoshii H, et al.

Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study.
Diabetes Ther. 2017 Oct;8(5):999-1013.

15. Mita T, Katakami N, Shiraiwa T, et al.

Dose-Dependent Effect of Sitagliptin on Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Post Hoc Analysis.
Diabetes Ther. 2017 Oct;8(5):1135-1146.

14. Shigiyama F, Kumashiro N, Furukawa Y, et al.

Characteristics of hepatic insulin-sensitive nonalcoholic fatty liver disease.
Hepatol Commun. 2017 Jul 29;1(7):634-647.

13. Satoh H, Ohira T, Moriya C, et al.

Effects of linagliptin vs.
voglibose on daily glucose excursions during continuous glucose monitoring of Japanese type 2 diabetes patients (L-CGM): A randomized, open-label, two-arm, parallel comparative trial.
Diabetes Metab. 2017 Dec;43(6):550-553.

12. Shigiyama F, Kumashiro N, Miyagi M, et al.

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.
Cardiovasc Diabetol. 2017 Jul 6;16(1):84.

11. Mita T, Katakami N, Shiraiwa T, et al.

The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis.
Diabetes Ther. 2017 Jun;8(3):693-704.

10. Mita T,Katakami N, Shiraiwa T, et al.

Relationship between frequency of hypoglycemic episodes and changes in carotid atherosclerosis in insulin-treated patients with type 2 diabetes mellitus.
Sci Rep. 2017 Jan 9;7:39965.

9. Ishii H, Niiya T, Ono Y, Inaba N, et al.

Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study.
Diabetol Metab Syndr. 2017 Jan 7;9:3.

8. Shigiyama F, Kumashiro N, Miyagi M, et al.

Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function.
J Diabetes Investig. 2017 May;8(3):330-340.

7. Fujitani Y, Fujimoto S, Takahashi K, et al.

Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP).
Diabetes Res Clin Pract. 2016 Nov;121:146-156.

6. Mita T, Katakami N, Shiraiwa T, et al.

Changes in carotid intima-media thickening in patients with type 2 diabetes mellitus: Subanalysis of the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation.
JDiabetes Investig. 2017 Mar;8(2):254-255.

5.Mita T, Katakami N, Shiraiwa T, et al.

Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.
Diabetes Care. 2016 Mar;39(3):455-64.

4.Mita T, Katakami N, Yoshii H, et al.

Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
Diabetes Care. 2016 Jan;39(1):139-48.

3.Fukuda M, Doi K, Sugawara M, et al.

Survey of Hypoglycemia in Elderly People With Type 2 Diabetes Mellitus in Japan.
J Clin Med Res. 2015 Dec;7(12):967-78.

2. Mita T, Katakami N, Shiraiwa T, et al.

Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor:the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE).
Diabetol Metab Syndr. 2014 Mar 10;6(1):35.

1. Katakami N, Mita T, Yoshii H, et al.

Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).
J Atheroscler Thromb. 2013;20(12):893-902.